Colony Stimulating Factors Current Market Dynamics & Future Outlook

By the end of 2004 the world market for Colony Stimulating Factors was valued at $3.6 billion, a growth of 11% over 2003. The market has been growing at an average annual growth rate of 16% over the previous 5 years.

Amgen's Neupogen (Filgrastim) will lose its key patent in major markets in 2006 opening the market for generics. Amgen is already preparing itself for this major patent loss by concentrating its marketing efforts on Neulasta (Peg-Filgrastim) its once-per-cycle long acting pegylated product and by offering little or no support to Neupogen.

Many generic companies have already synthesized and tested own filgrastim products and are ready to launch their products in major markets once patent is expired. Many licensing opportunities are available and possibilities of a super generic are there.

Colony Stimulating Factors, Current Market Dynamics & Future Outlook is a timely strategic consulting report from ASInsights assessing both the technology status and the competitive landscape of Colony Stimulating Factors and Interleukin-2 markets. The report examines both the US, the European and the Japanese markets. It profiles leading products and companies and offer revenue forecasts to the year 2010.

The report also assesses market attractiveness, the potential for generic entries and for the first time, gives profiles of CSFs production initiatives in developing countries like Cuba, China and India.

Report Code: ASI0412-R02

Date Published: December 2004

Number of Pages: 54

Report Price:

US$780 - PDF file by email

US$1,560 - Site License

View Table of Contents...

Price
PDF Format $780.00
Printed Copy (including shipping) $980.00
PDF Site Licence $1,560.00